A Study to Evaluate Mepolizumab to Treatment Chronic Spontaneous Urticaria

Overview

About this study

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

    •  
  • Male and female patients, 18 years or older..
  • Clinical and/or histopathological diagnosis of conventional CSU.
  • Urticaria control test score ≤ 12 (corresponds to poorly controlled disease).
  • Unresponsive to oral antihistamine therapy.
  • Good general health as confirmed by medical history.
  • Patients who are willing and capable of cooperating to the extent and degree required by the protocol.
  • Patients who read and sign an approved informed consent for this study.
  • Patients who are able to register on the Mayo portal to access video visit platform.

Exclusion Criteria:

    •  
  • Vulnerable study population.
  • If you are female and pregnant.
  • Biopsy proven neutrophilic rich urticarial which is unlikely to respond to mepolizumab given the postulated therapeutic mechanism.
  • Known Patients able to learn and demonstrate proper SQ injection technique.
  • history of adverse reaction to mepolizumab (Nucala).
  • Asthma requiring inhaled corticosteroids.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Sluzevich, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20426510

Mayo Clinic Footer